跳至主要内容
临床试验/NCT00151437
NCT00151437已完成4 期

A Multi-Center, Open-Label Study For The Compassionate Use Of Pegvisomant In Acromegalic Patients Refractory To Conventional Therapy and For Patients Who Received The Product During The Clinical Development Program.

Pfizer6 个研究点 分布在 1 个国家目标入组 30 人开始时间: 2004年11月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Pfizer
入组人数
30
试验地点
6
主要终点
Patient's IGF-1 levels normalize signs and symptoms of acromegaly normalize

研究概览

简要总结

The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the safety and tolerability of SOMAVERT.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects must have participated and completed the previous Pegvisomant studies or have shown to be unresponsive to other conventional therapies

排除标准

  • ALT/AST>3 times the ULN or have hepatic disease
  • have severe visual field loss, cranial nerve palsies or intracranial HTN that requires surgery to decompress the tumor
  • unwilling to self-administer the medication.

结局指标

主要结局

Patient's IGF-1 levels normalize signs and symptoms of acromegaly normalize

次要结局

  • Pegvisomant demonstrates continued safety and efficacy

研究者

发起方
Pfizer
申办方类型
Industry

研究点 (6)

Loading locations...

相似试验